logo
Schedule a Meeting

News

Faster Targeted Therapy with the T2Bacteria Detection of a Polymicrobial Infection

T2Bacteria case study highlighting the early detection of a polymicrobial infection

University of Louisville Health | Louisville, KY

Presentation

A 51-year-old male presented with acute decompensated heart failure.

Patient History

The patient had a history of intravenous (IV) drug use, hepatitis C, cirrhosis, and diabetes.

The patient also had urinary symptom complaints that began with admission, and the patient was on ceftriaxone (1 gram IV) for Escherichia coli from a previous urine culture.

Evaluation and Treatment Decision

  • On hospital day 4, the patient experienced a new septic event, and T2Bacteria and blood cultures were ordered.
  • Vancomycin was added and ceftriaxone was escalated to piperacillin/tazobactam.
  • ≈ 6 hours after the blood draw, T2Bacteria was positive for Escherichia coli and Staphylococcus aureus.
  • On hospital day 5, ≈19 hours after the blood draw, the blood culture was also positive for Staphylococcus aureus, but never grew Escherichia coli.
  • The patient was de-escalated from piperacillin/tazobactam to ceftriaxone to complete a 7-day course and continued vancomycin.

The identification of an additional Staphylococcus aureus infection allowed for directed therapy with the addition of vancomycin.

Learn More

To learn more about this case, watch the Learning Lounge from IDWeek 2024
Watch Presentation

1. Ross, A. Pharmacists’ Perspective: Real-World T2Bacteria® Experience, IDWeek. 2024.

Faster Time to Targeted Therapy with T2Bacteria

In both of these clinical case studies, T2Bacteria® identified the causative pathogen days sooner than blood culture and allowed for the earlier initiation of targeted therapy.1

Butler Health System | Butler, PA

Case 1
Age and Sex: 70-year-old male

Presentation: The patient presented with shortness of breath, hypothermia, hypertension and was admitted. The patient had no sepsis indicators and no action was taken for sepsis screening.

Vitals: T = 99.8; BP = 152/86; P = 70

Evaluation and Treatment

Day 0

• WBC = 23.2, MDW* = 23.05 lactic acid = 1.0,PCT = .32

• T2Bacteria Result: The T2Bacteria Panel was positive for Enterococcus faecium, and the patient was initiated on targeted therapy

Day 1

• Blood culture confirmed Enterococcus faecium.

T2Bacteria allowed for targeted therapy 20 hours faster than blood culture alone.

Case 2
Age and Sex: 67-year-old male

Presentation: The patient presented with altered mental status and hypotension, and was admitted. The patient had no sepsis indicators and no action was taken for sepsis screening.

Vitals: T not taken, BP= 62/44, P = 53

Evaluation and Treatment

Day 0

• WBC = 24.7, MDW* = 23.98, lactic acid = 1.0, PCT = 4.25

Day 1

• T2Bacteria Result: The T2Bacteria Panel was positive for Pseudomonas aeruginosa, and the patient was initiated on targeted therapy

Day 3

• Blood culture confirmed Pseudomonas aeruginosa.

T2Bacteria allowed for targeted therapy 37 hours faster than blood culture alone.

Download Case Studies

Please fill out this form to download the case studies

*This institution uses an algorithm combining Monocyte Distribution Width (MDW) from Beckman Coulter and white blood count (WBC) metrics as an indicator to run T2Bacteria.

  1. Patterson, R., Katsaros, S., Industry Showcase, ASM 2023

Popular Posts

According to the CDC, of the 154 million prescriptions for antibiotics written in doctors’ offices and emergency departments each year, 30% are unnecessary.12

PUBLICATIONS

Over 200 studies published in peer-reviewed journals have featured T2MR in a breadth of applications.

Read Now!

T2 BIOSYSTEMS OVERVIEW

T2 Biosystems, an emerging leader in the field of in vitro diagnostics, is dedicated to saving lives and reducing the cost of healthcare by empowering clinicians to effectively treat patients faster than ever before. T2 Biosystems is focused on addressing critical unmet needs in healthcare starting with sepsis, one of the deadliest and most expensive conditions in hospitals today.

The T2Dx Instrument, the T2Bacteria and T2Candida Panels have received marketing authorization from the U.S. Food and Drug Administration. All other T2 Biosystems products are considered investigational and for research use only.

T2 Biosystems®, T2MR®, T2Bacteria®, T2Candida®, T2Resistance® and T2Dx® are registered trademarks of T2 Biosystems, Inc. “T2Biosystems” and the T2 Biosystems, Inc. logo design are registered trademarks or trademarks of T2Biosystems, Inc. All software and documentation is subject to T2 Biosystems, Inc. copyrights. All rights reserved. T2Direct Diagnostics™, T2HemoStat™, T2Plex™, T2Cauris™, T2Lyme™ and T2SARS-CoV-2™ are trademarks of T2 Biosystems, Inc.

© 2024 T2 Biosystems, Inc.

SITEMAP

FOLLOW US ON SOCIAL

Linkedin-in Twitter

Please tell us where you are visiting from: United States | Outside the United States